投资者可于 2023 年 05 月 24 日(星期三)至 05 月 30 日(星期二)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@jalon.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 洛阳建龙微纳新材料股份有限公司（以下简称"公司"）已于 2023 年 4 月 26 日发布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经营成果、财务状况，公司计划于 2023 年 05 月 31 日下午 13:00-14:30 举 行 2022 年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以视频结合网络互动召开，公司将针对 2022 年度经营成 果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围 内就投资者普遍关注的问题进行回答。 | 证券代码：688357 | 证券简称：建龙微纳 | 公告编号：2023-053 | | --- | --- | --- | | 转债代码：118032 | 转债简称：建龙转债 | | 洛阳建龙微纳新材料股份有限公司 关于召开 2022 年度业绩说明 ...

证券代码：688357 证券简称：建龙微纳 公告编号：2023-049 转债代码：118032 转债简称：建龙转债 洛阳建龙微纳新材料股份有限公司 关于参加河南辖区上市公司 2023 年投资者网上集体 接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为进一步加强与投资者的互动交流，洛阳建龙微纳新材料股份有限公司（以 下简称"公司"）定于 2023 年 5 月 18 日（周四）16:00-17:20 参加在全景网举 办的"真诚沟通 传递价值"河南辖区上市公司 2023 年投资者网上集体接待日 活动。本次活动将采用网络远程的方式举行，投资者可登录"全景·路演天下" （http://rs.p5w.net）参与本次互动交流。 出席本次网上集体接待日活动的人员有：公司副总裁兼董事会秘书李怡丹女 士及相关工作人员（如有特殊情况，参会人员将可能进行调整）。主要就公司 2022 年年报、公司治理、发展战略、经营状况、融资计划、投资者保护、可持续发展 等投资者所关心的问题进行沟通交流。 欢迎广大投资者积极参与。 特此公告。 ...

Financial Performance - The company's operating revenue for 2022 was CNY 853.79 million, a decrease of 2.72% compared to 2021[22]. - Net profit attributable to shareholders decreased by 28.16% to CNY 197.86 million, while net profit after deducting non-recurring gains and losses fell by 37.20% to CNY 154.36 million[22]. - Total assets increased by 29.99% to CNY 2.19 billion, and net assets attributable to shareholders rose by 26.55% to CNY 1.55 billion[22]. - Basic earnings per share were CNY 3.36, down 29.41% year-on-year, while the weighted average return on equity was 13.89%, a decrease of 10.27 percentage points[23][25]. - The company's operating revenue for the reporting period was CNY 853.79 million, a decrease of 2.72% compared to the previous year[94]. - Operating costs increased by 22.09% to CNY 572.85 million, primarily due to rising prices of key raw materials such as lithium salts[94]. Cash Flow and Investments - The net cash flow from operating activities decreased by 108.40%, primarily due to rising procurement costs from lithium salts and other raw materials[24]. - The net cash flow from operating activities showed a negative trend throughout the year, with Q4 reporting a net cash outflow of -¥17,188,292.47[27]. - The net cash flow from investing activities was -CNY 59.13 million, reflecting an increase in the recovery of financial management funds[95]. - The net cash flow from financing activities was CNY 124.11 million, primarily due to the issuance of shares to specific investors[95]. Research and Development - Research and development expenses accounted for 4.45% of operating revenue, a slight decrease from 4.80% in the previous year[24]. - The company’s R&D investment for 2022 was 38.00 million yuan, resulting in 7 new invention patents, bringing the total to 32 authorized patents[37]. - The company is collaborating with various universities and research institutes to enhance its R&D capabilities and product development[67]. - The company has established several research and innovation platforms to support technological advancements, including the "Henan Province Inorganic Adsorption Materials Academician Workstation" and "Henan Province Adsorption Molecular Sieve Engineering Technology Research Center"[128]. Market and Competitive Position - The company is positioned in the chemical raw materials manufacturing industry, facing competition from both international and domestic players[44]. - The company is a leader in the domestic molecular sieve industry, continuously increasing R&D investment and expanding production scale to meet rising market demand[53]. - The global molecular sieve market size was $12.8 billion in 2021 and is projected to reach $15.7 billion by 2026, with a compound annual growth rate (CAGR) of 4.17% from 2021 to 2026[55]. - The company aims to enhance its competitive edge through technological innovation and resource integration, leading to a gradual increase in market concentration[45]. Governance and Compliance - The company has received a standard unqualified audit report from its accounting firm, indicating the financial statements are accurate and complete[5]. - The company confirmed that all board members attended the board meeting, ensuring governance compliance[5]. - The company held one annual general meeting and one extraordinary general meeting during the reporting period, with all proposed resolutions approved by shareholders[163]. - The board of directors held nine meetings during the year, reviewing and approving key matters including the annual report[158]. Risks and Challenges - The company has outlined potential risk factors in its operations, which can be found in the management discussion and analysis section[4]. - The company is exposed to raw material price fluctuations, particularly for lithium salts and sodium hydroxide, which could adversely affect performance if prices rise significantly[87]. - The company faces risks related to product iteration, as competitors may introduce more efficient and environmentally friendly molecular sieves, potentially impacting market share[85]. - The company is at risk of losing core technical personnel, which could impact its innovation capabilities and product development[86]. Strategic Initiatives - The company plans to distribute a cash dividend of 10.00 RMB per 10 shares (including tax) and to increase capital by 4 shares for every 10 shares held, resulting in a total capital increase of 23,779,939 shares[5]. - The company plans to expand its market presence and enhance product development in response to rising raw material costs[24]. - The company aims to enhance the adsorption capacity and selectivity of molecular sieve products through exchange modification, facilitating import substitution[58]. - Future strategies include expanding into hydrogen purification, coal-to-ethanol, and environmental remediation fields, enhancing product structure and ensuring sustainable development[152].

Financial Performance - The company's operating revenue for Q1 2023 was CNY 325,977,322.88, representing a year-on-year increase of 65.58%[5] - The net profit attributable to shareholders for the same period was CNY 60,546,221.78, up 38.05% compared to the previous year[5] - Basic earnings per share for Q1 2023 reached CNY 1.02, reflecting a growth of 34.21%[6] - Total comprehensive income for Q1 2023 was RMB 58,980,004.08, compared to RMB 43,598,960.75 in Q1 2022, an increase of 35.3%[20] - Operating profit for Q1 2023 was RMB 68,741,645.39, up 35.4% from RMB 50,778,720.23 in Q1 2022[19] Cash Flow and Assets - The net cash flow from operating activities increased significantly by 332.05%, amounting to CNY 46,600,806.44[5] - Cash flow from operating activities for Q1 2023 was RMB 46,600,806.44, significantly higher than RMB 10,785,892.97 in Q1 2022[22] - Cash and cash equivalents stood at CNY 911,566,687.84, significantly higher than CNY 197,605,288.15 at the end of the previous year, showing an increase of approximately 360%[14] - Cash and cash equivalents at the end of Q1 2023 amounted to RMB 802,448,878.91, compared to RMB 434,267,983.98 at the end of Q1 2022, reflecting a 84.7% increase[22] - The company reported cash inflows from investment activities of RMB 812,302,971.01 in Q1 2023, slightly down from RMB 813,028,481.13 in Q1 2022[22] - The net cash flow from financing activities for Q1 2023 was RMB 690,419,913.59, compared to RMB 190,064,928.60 in Q1 2022, indicating a substantial increase[22] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,029,548,016.96, an increase of 38.58% from the end of the previous year[6] - As of March 31, 2023, the total current assets amounted to CNY 1,917,416,542.88, an increase from CNY 1,136,273,681.28 as of December 31, 2022, reflecting a growth of approximately 68.7%[14] - The total liabilities were reported at CNY 1,294,341,880.71, up from CNY 636,634,383.38, representing a growth of approximately 103.5%[16] - The total equity attributable to shareholders increased to CNY 1,735,206,136.25 from CNY 1,549,425,357.84, marking an increase of about 12%[16] Research and Development - Research and development expenses totaled CNY 13,840,995.82, which is 67.07% higher than the previous year[6] - The proportion of R&D expenses to operating revenue was 4.25%, an increase of 0.04 percentage points[6] - The company attributed revenue growth to the gradual release of new production capacity and optimization of product structure[8] - The increase in net profit was driven by the gradual release of new capacity and enhanced brand influence[8] - The company plans to continue advancing its R&D projects and expanding its production capabilities[8] - Research and development expenses for Q1 2023 totaled RMB 13,840,995.82, compared to RMB 8,284,636.90 in Q1 2022, indicating a 67.5% increase[18] Other Information - The company has not disclosed any new product developments or market expansion strategies in the current report[12] - There are no significant changes in the shareholder structure or related party transactions reported for this quarter[12] - The company has adopted new accounting standards starting from 2023, which may involve adjustments to the financial statements at the beginning of the year[23]

Financial Performance - The company's operating revenue for Q3 2022 was ¥213,569,980.41, a decrease of 27.88% compared to the same period last year[5]. - The net profit attributable to shareholders was ¥53,608,533.20, down 45.73% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥36,911,339.22, a decline of 60.37% compared to the previous year[5]. - The basic earnings per share for the period was ¥0.91, a decrease of 46.78% year-on-year[6]. - Net profit for the third quarter of 2022 was ¥135,272,625.60, compared to ¥200,619,524.75 in the same quarter of 2021, reflecting a decrease of approximately 32.5%[20]. - The total comprehensive income for the third quarter of 2022 was CNY 131,214,409.68, a decrease from CNY 190,621,471.44 in the same period of 2021, representing a decline of approximately 31.1%[21]. - Basic and diluted earnings per share for Q3 2022 were CNY 2.30, down from CNY 3.47 in Q3 2021, reflecting a decrease of about 33.7%[21]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,006,381,034.84, an increase of 19.31% from the end of the previous year[6]. - The company's total assets as of the end of the third quarter of 2022 amounted to ¥2,006,381,034.84, compared to ¥1,681,652,249.15 at the end of the same quarter in 2021, marking an increase of about 19.3%[19]. - Total liabilities increased to ¥536,445,812.61 in the third quarter of 2022 from ¥457,312,255.53 in the same quarter of 2021, representing a rise of approximately 17.3%[18]. - The company's cash and cash equivalents were not explicitly detailed, but total current assets reached ¥1,047,097,090.35, up from ¥919,230,186.16 in the previous year, indicating a growth of about 13.9%[18]. Cash Flow - The cash flow from operating activities showed a net outflow of ¥15,399,229.33, representing a decrease of 104.57% compared to the previous year[6]. - Cash inflows from operating activities for the first three quarters of 2022 totaled CNY 456,283,729.84, compared to CNY 554,609,430.46 in the same period of 2021, indicating a decline of approximately 17.7%[23]. - The net cash flow from operating activities for the first three quarters of 2022 was negative CNY 15,399,229.33, contrasting with a positive CNY 336,714,681.17 in the previous year[23]. - Cash inflows from investment activities for the first three quarters of 2022 amounted to CNY 3,252,055,198.28, an increase from CNY 2,484,711,308.42 in 2021, representing a growth of about 30.9%[23]. - The net cash flow from investment activities was negative CNY 116,428,289.62 for the first three quarters of 2022, compared to negative CNY 185,925,680.02 in the same period of 2021, showing an improvement[23]. - Cash and cash equivalents at the end of Q3 2022 were CNY 88,245,151.50, down from CNY 207,822,627.82 at the end of Q3 2021, a decrease of approximately 57.6%[24]. - The net cash flow from financing activities for the first three quarters of 2022 was CNY 119,508,311.47, compared to negative CNY 70,730,847.22 in the same period of 2021, indicating a significant turnaround[24]. Shareholder Information - The top shareholder, Li Jianbo, holds 14,350,000 shares, representing 24.23% of the total shares[13]. - The second-largest shareholder, Shenzhen Shenyunlong Investment Development Co., Ltd., owns 5,000,000 shares, accounting for 8.44%[13]. - The company has a total of 5,502 common shareholders as of the report date[13]. - The report indicates that there are no significant changes in the status of major shareholders participating in margin financing and securities lending[15]. Research and Development - Research and development expenses totaled ¥10,735,812.47, accounting for 5.03% of operating revenue, which is an increase of 1.23 percentage points year-on-year[6]. - Research and development expenses for the first three quarters of 2022 were ¥28,740,413.54, slightly higher than ¥28,002,405.20 in the same period of 2021, showing an increase of approximately 2.6%[19]. Other Information - The company received government subsidies that were lower than the same period last year, impacting net profit negatively[11]. - The decline in net profit was primarily due to rising raw material costs outpacing revenue growth[11]. - The company has not disclosed any new strategies or future outlook in the current report[16]. - There are no significant audit opinions applicable to the financial statements for the reporting period[16].

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2022, representing a year-on-year increase of 15%[1]. - The company's operating revenue for the first half of 2022 was approximately CNY 404.31 million, representing a 30.23% increase compared to CNY 310.46 million in the same period last year[22]. - The net profit attributable to shareholders decreased by 19.81% to approximately CNY 81.66 million, down from CNY 101.84 million in the previous year[22]. - The basic earnings per share for the first half of 2022 was CNY 1.39, a decrease of 21.02% from CNY 1.76 in the same period last year[22]. - The net cash flow from operating activities dropped significantly by 99.61% to approximately CNY 622,765, primarily due to increased cash payments for goods and services[22]. - The company has set a performance guidance of RMB 2.5 billion in revenue for the full year 2022, reflecting a growth target of 20%[1]. - The company's gross profit margin improved to 35%, up from 30% in the same period last year[1]. - The decline in net profit was primarily due to rising prices of raw materials and energy, leading to significantly higher production costs[22]. Research and Development - Research and development expenses increased by 25%, totaling RMB 150 million, focusing on new technology innovations[1]. - Research and development expenses accounted for 4.45% of operating revenue, a decrease of 0.94 percentage points from the previous year[22]. - The company has established a comprehensive innovation system, increasing R&D investment to achieve breakthroughs in core technologies[29]. - The company collaborates with universities and research institutions to enhance its R&D capabilities and accelerate the commercialization of research outcomes[30]. - The company has completed multiple technology reserves, including denitrification molecular sieves and catalysts, and has obtained several national invention patents[48]. - The number of R&D personnel increased from 61 to 78, with R&D personnel accounting for 10.54% of the total workforce[60]. Market Expansion and Strategy - The company plans to launch two new products in Q3 2022, targeting a market expansion of 10% in the next fiscal year[1]. - The company has outlined a strategic goal to enter the Southeast Asian market by the end of 2022, aiming for a market share of 5%[1]. - The company aims to support the "dual carbon" goals through the development of molecular sieve products that facilitate the transition to high-quality development in the petrochemical industry[38]. - The company is actively diversifying its product applications into energy and chemical fields, including coal-to-ethanol and coal-to-propylene[32]. Environmental Compliance and Sustainability - The company emphasizes environmental protection and has invested in new generation environmental treatment systems to reduce production pollution[66]. - The company has implemented a comprehensive wastewater treatment process, including initial sedimentation and pH adjustment, to manage production wastewater[114]. - The company has established a solid waste management system in compliance with national standards to prevent secondary pollution[114]. - The company has installed pollution control facilities, including cyclone separators and low-nitrogen burners, to treat exhaust gases[114]. - The company has reduced electricity consumption and greenhouse gas emissions by optimizing processes in response to national "carbon neutrality" policies[121]. - The company has not reported any significant changes in its environmental compliance status[112]. Risks and Challenges - Risk factors related to supply chain disruptions were highlighted, with potential impacts on production timelines[1]. - The company faces market competition risks from both international and domestic molecular sieve manufacturers, which could weaken its core competitiveness if it fails to innovate[72]. - The company is exposed to risks from rising raw material prices, which could adversely affect its gross margin and profitability if product sales prices do not increase correspondingly[72]. - The company’s overseas market expansion may be negatively impacted by a potential global economic downturn affecting the capacity release and market development of its subsidiary in Thailand[73]. Shareholder Information - The company raised a total of CNY 625.83 million in its initial public offering, with a net amount of CNY 569.92 million after deducting issuance costs[157]. - The total number of shares increased to 59,228,885 after the issuance of 1,235,039 new shares[168]. - The largest shareholder, Li Jianbo, holds 14,350,000 shares, representing 24.23% of total shares[174]. - The top ten shareholders collectively hold a significant portion of the company's equity, with the top three alone accounting for over 39%[174]. - The company has a diverse shareholder base, including both individual and institutional investors[176]. Financial Position - The company's total assets increased by 19.11% to approximately CNY 2.00 billion, up from CNY 1.68 billion at the end of the previous year[22]. - The company's total liabilities reached CNY 588,538,881.07, up from CNY 457,312,255.53, indicating a growth of around 28.7%[190]. - Owner's equity increased to CNY 1,414,493,507.62 from CNY 1,224,339,993.62, showing a growth of about 15.5%[190]. - Cash and cash equivalents amounted to CNY 174,430,726.32, up from CNY 137,604,402.31, representing a growth of approximately 27%[193].

Financial Performance - The company's operating revenue for Q1 2022 was CNY 196,874,549.15, representing a year-on-year increase of 56.95%[5] - The net profit attributable to shareholders was CNY 43,859,750.57, reflecting a growth of 33.59% compared to the same period last year[5] - Basic earnings per share increased by 33.33% to CNY 0.76, driven by the growth in net profit[6] - Total operating revenue for Q1 2022 reached ¥196,874,549.15, a significant increase of 57.0% compared to ¥125,436,139.42 in Q1 2021[21] - Operating profit for Q1 2022 was ¥50,778,720.23, up 47.9% from ¥34,344,529.74 in Q1 2021[22] - Net profit attributable to shareholders for Q1 2022 was ¥43,859,750.57, representing a 33.6% increase from ¥32,831,979.69 in Q1 2021[22] - Basic earnings per share for Q1 2022 was ¥0.76, compared to ¥0.57 in Q1 2021, reflecting a growth of 33.3%[23] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 78.76%, amounting to CNY 10,785,892.97, primarily due to increased cash payments for goods and services[6] - Cash flow from operating activities for Q1 2022 was ¥10,785,892.97, a decrease of 78.8% from ¥50,777,671.14 in Q1 2021[25] - The net cash flow from investing activities was $136,509,698.45, a significant improvement compared to a negative cash flow of $37,391,214.10 in the previous period, indicating a positive shift in investment performance[27] - The total cash and cash equivalents at the end of the period amounted to $434,267,983.98, up from $126,968,233.89 in the previous period, reflecting a net increase of $337,281,493.76[27] - The net cash flow from financing activities was $190,064,928.60, contrasting with a negative cash flow of $20,194,750.00 in the prior period, showcasing a strong financing position[27] - The total cash inflow from financing activities was $193,999,926.12, with cash outflows totaling $3,934,997.52, indicating effective capital management[27] - The company experienced a foreign exchange impact on cash and cash equivalents of -$79,026.26, which is a decrease compared to -$1,857,125.12 in the previous period[27] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 2,041,628,197.18, marking a 21.41% increase from the previous year[6] - As of March 31, 2022, the company's total assets reached RMB 2,041,628,197.18, an increase from RMB 1,681,652,249.15 as of December 31, 2021, reflecting a growth of approximately 21.4%[17] - The total current liabilities increased to RMB 552,415,494.93 from RMB 429,220,526.80, representing an increase of approximately 28.7%[17] - Total liabilities increased to ¥580,031,151.89 in Q1 2022, up from ¥457,312,255.53 in Q1 2021, marking a rise of 26.8%[21] - Total equity attributable to shareholders rose to ¥1,461,597,045.29 in Q1 2022, compared to ¥1,224,339,993.62 in Q1 2021, an increase of 19.4%[21] Research and Development - Research and development expenses totaled CNY 8,284,636.90, accounting for 4.21% of operating revenue, a decrease of 2.15 percentage points[6] - Research and development expenses for Q1 2022 were ¥8,284,636.90, an increase from ¥7,980,224.07 in Q1 2021, indicating a focus on innovation[21] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,236[11] - The largest shareholder, Li Jianbo, held 14,350,000 shares, representing 24.23% of the total shares[11] Strategic Direction and Market Activity - The company has not disclosed any new product developments or market expansion strategies in the current report[14] - There are no significant changes in the shareholder structure or related party transactions reported for this quarter[13] - The company did not report any new acquisitions or significant market expansions during this quarter, focusing instead on optimizing existing operations[28] - There were no new product launches or technological advancements mentioned in the earnings call, suggesting a period of consolidation[28] - The company has not indicated any changes to its strategic direction or new initiatives for the upcoming quarters[28] Other Financial Metrics - The weighted average return on equity was 3.05%, a decrease of 0.26 percentage points compared to the previous year[6] - Other comprehensive income for Q1 2022 was a loss of ¥260,789.82, compared to a loss of ¥2,225,344.40 in Q1 2021, showing improvement[22] - The company's accounts receivable increased to RMB 55,431,909.15 from RMB 39,781,058.01, reflecting a growth of approximately 39.5%[16] - The total non-current assets amounted to RMB 857,204,599.94, up from RMB 762,422,062.99, indicating an increase of about 12.4%[17] - The company reported a total of RMB 235,000,000.00 in trading financial assets, down from RMB 450,000,000.00, representing a decrease of approximately 47.8%[16] - The company's short-term borrowings and other financial liabilities were not detailed in the provided data, indicating a focus on liquidity management[17] - The cash flow from investment activities decreased from $899,967,957.81 to $676,518,782.68, reflecting a reduction in investment expenditures[27] - The company’s management has confirmed adherence to the new accounting standards effective from 2022, ensuring compliance and transparency in financial reporting[27]

Financial Performance - The company's operating revenue for 2021 was CNY 877,645,727.41, representing a 94.36% increase compared to CNY 451,549,981.64 in 2020[21]. - The net profit attributable to shareholders increased by 116.22% to CNY 275,405,809.23 from CNY 127,370,724.24 in the previous year[23]. - The net profit after deducting non-recurring gains and losses rose by 125.02% to CNY 245,782,797.05, up from CNY 109,229,410.44 in 2020[23]. - The net cash flow from operating activities increased by 204.52% to CNY 387,777,067.99, compared to CNY 127,341,756.34 in the previous year[23]. - The total assets grew by 42.23% to CNY 1,681,652,249.15 from CNY 1,182,374,890.54 in 2020[23]. - The net assets attributable to shareholders increased by 25.62% to CNY 1,224,339,993.62, compared to CNY 974,606,512.80 at the end of 2020[23]. - Basic earnings per share reached CNY 4.76, a 116.36% increase from CNY 2.2 in the previous year[22]. - The weighted average return on equity was 24.16%, an increase of 10.29 percentage points from 13.87% in 2020[22]. Dividend Distribution - The company plans to distribute a cash dividend of 15.00 RMB per 10 shares, totaling approximately 86,990,769.00 RMB, which accounts for 31.59% of the net profit attributable to shareholders for the year 2021[6]. - The cash dividend policy prioritizes cash distribution, with a minimum of 80% cash dividend for mature companies without significant capital expenditure plans[188]. - The company's cash distribution conditions include positive distributable profits and sufficient cash flow, ensuring no impact on ongoing operations[188]. Research and Development - Research and development expenses accounted for 4.80% of operating revenue, up from 4.24% in 2020[22]. - The company reported a significant increase in R&D expenses, with a total of ¥42,145,074.20 in the current year, representing a 120.23% increase compared to ¥19,137,029.89 in the previous year[64]. - The company emphasizes R&D investment and has established a dual-driven R&D model combining independent and collaborative research, enhancing its innovation capabilities[41]. - The company has established joint laboratories with Nankai University and Dalian University of Technology to enhance R&D efforts in carbon capture and molecular sieve technology[62]. - The R&D team is composed of experienced professionals, contributing to the company's innovation and product development[75]. Market Position and Growth - The company attributed its revenue growth to the expanding market for molecular sieves and enhanced production capacity[23]. - The molecular sieve market was valued at $6.4 billion in 2020 and is projected to reach $8.49 billion by 2028, with a compound annual growth rate (CAGR) of 3.8% from 2021 to 2028[54]. - The company is one of the leaders in the domestic molecular sieve industry, with a production scale that ranks among the top globally, continuously expanding its production capacity[44]. - The industrial gas market, where molecular sieves are essential, is expected to grow at a rate approximately 1.4 times that of GDP, indicating increasing demand for molecular sieves[44]. - The company is well-positioned to benefit from the growing demand for molecular sieves in both industrial and medical applications, driven by aging populations and increasing health awareness[50]. Corporate Governance - The board of directors and management have confirmed the accuracy and completeness of the annual report, with no significant omissions or misleading statements[5]. - The company has established a complete governance structure, ensuring independent operation of the board of directors, supervisory board, and management team, promoting healthy and sustainable development[156]. - The company has implemented strict information disclosure practices, ensuring transparency and equal access to information for all shareholders[157]. - The company has not faced any issues regarding independence or operational autonomy from its controlling shareholders[158]. - The company has established a compensation and assessment committee under the board of directors to oversee the remuneration and evaluation of senior executives[200]. Risks and Challenges - The company has outlined potential risk factors in its operations, which are detailed in the management discussion and analysis section[5]. - The company faces risks related to product iteration, as competitors may introduce more efficient molecular sieves, potentially impacting market share[80]. - The company is exposed to raw material price fluctuations, which could adversely impact performance if sales prices do not adjust accordingly[83]. - The ongoing COVID-19 pandemic may affect the capacity release and market expansion of the company's overseas projects[87]. - The company is subject to macroeconomic risks that could impact its operations and financial performance[86]. Production and Capacity - The company has a total production capacity of 45,000 tons for molded molecular sieves and activated molecular sieves, positioning it favorably in the domestic market compared to peers[54]. - The company added 10,000 tons of molecular sieve raw powder capacity and 22,000 tons of molded molecular sieve capacity during the reporting period[134]. - The average capacity utilization rates for molecular sieve raw powder, activated powder, molded molecular sieve, and activated alumina were 106.45%, 79.37%, 89.10%, and 63.32% respectively[135]. - The company has developed molecular sieve products with a production capacity of 41,000 tons for raw powder and 42,000 tons for shaped molecular sieves as of December 31, 2021[74]. Employee and Management - The total number of employees in the parent company is 659, and in major subsidiaries, it is 63, resulting in a total of 722 employees[184]. - The company has established a salary policy that emphasizes performance-based distribution and aims to enhance employee motivation and innovation[185]. - The company has a training plan that includes targeted skills training for employees based on their positions and levels, as well as management training to improve leadership capabilities[186]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 6.6922 million RMB[171]. - The company has implemented a performance assessment mechanism for senior management to ensure accountability[200].

Financial Performance - The company's revenue for Q3 2021 reached ¥296,130,931.33, representing a year-on-year increase of 115.35%[5] - Net profit attributable to shareholders for the same period was ¥98,776,619.60, up 129.72% compared to the previous year[5] - The basic earnings per share for Q3 2021 was ¥1.71, reflecting an increase of 131.08% year-on-year[6] - Total operating revenue for the first three quarters of 2021 reached ¥606,591,150.96, a significant increase from ¥319,540,960.44 in the same period of 2020, representing an increase of approximately 89.9%[19] - Net profit for the first three quarters of 2021 was ¥200,619,524.75, up from ¥93,779,491.23 in 2020, indicating a growth of approximately 113.4%[21] - The total comprehensive income for the third quarter of 2021 was CNY 190,621,471.44, compared to CNY 93,779,491.23 in the same period of 2020, representing an increase of 103.5%[22] - Basic and diluted earnings per share for Q3 2021 were CNY 3.47, up from CNY 1.62 in Q3 2020, reflecting a growth of 114.2%[22] Assets and Liabilities - Total assets as of the end of the reporting period amounted to ¥1,576,907,500.35, a growth of 33.37% from the previous year[6] - The total assets as of the end of the third quarter of 2021 amounted to ¥1,576,907,500.35, compared to ¥1,182,374,890.54 at the end of the previous year, marking an increase of about 33.4%[17] - Total liabilities as of the end of the third quarter of 2021 were ¥437,534,048.14, up from ¥207,768,377.74 in the previous year, which is an increase of approximately 110.9%[17] - The company's fixed assets were valued at ¥514,884,937.70, compared to ¥351,455,661.48 in the previous year, reflecting an increase of about 46.5%[17] - Total liabilities amounted to 207,768,377.74, with current liabilities at 192,200,265.44[28] - Non-current liabilities totaled 15,568,112.30, including deferred income of 11,669,186.06 and deferred tax liabilities of 3,898,926.24[28] Cash Flow - The net cash flow from operating activities was ¥336,714,681.17, an increase of 265.54% compared to the same period last year[6] - Cash inflow from operating activities for the first three quarters of 2021 was CNY 554,609,430.46, significantly higher than CNY 239,304,252.47 in the same period of 2020, marking an increase of 131.7%[24] - The net cash flow from operating activities for the first three quarters of 2021 was CNY 336,714,681.17, compared to CNY 92,113,454.12 in 2020, indicating a growth of 264.5%[24] - The net cash flow from investment activities for the first three quarters of 2021 was -CNY 185,925,680.02, a decrease from CNY 113,788,066.39 in 2020[24] - The net cash flow from financing activities for the first three quarters of 2021 was -CNY 70,730,847.22, compared to -CNY 91,925,769.50 in 2020, showing an improvement of 23.0%[25] Research and Development - Research and development expenses totaled ¥11,267,299.30, which is 3.80% of revenue, marking an increase of 0.41 percentage points year-on-year[6] - Research and development expenses for the first three quarters of 2021 totaled ¥28,002,405.20, compared to ¥11,464,272.78 in 2020, indicating an increase of approximately 144.4%[19] Equity - The total equity attributable to shareholders was ¥1,139,373,452.21, reflecting a year-on-year increase of 16.91%[6] - The total equity attributable to shareholders of the parent company was ¥1,139,373,452.21, up from ¥974,606,512.80 in the previous year, indicating an increase of approximately 16.9%[17] Operational Insights - The company attributed revenue growth to the gradual release of new production capacity and optimization of product structure[9] - The company completed the construction and commissioning of new production lines in the first half of 2021, contributing to increased capacity and revenue[9] - The company reported a significant increase in sales revenue, with cash received from sales of goods and services amounting to CNY 516,069,512.01 for the first three quarters of 2021, compared to CNY 225,407,141.34 in 2020, an increase of 129.0%[23] Future Outlook - The company has not disclosed any significant new product developments or market expansion strategies during the reporting period[14] - There were no significant mergers or acquisitions reported in the third quarter of 2021[14] - The company did not provide specific future guidance or outlook for the upcoming quarters[14] - The company has implemented new leasing standards starting from 2021, which may impact financial reporting and asset management strategies moving forward[26]

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2021, representing a year-on-year increase of 20%[14]. - The company's operating revenue for the first half of the year reached approximately CNY 310.46 million, representing a 70.56% increase compared to the same period last year[22]. - The net profit attributable to shareholders increased by 100.56% year-on-year, amounting to approximately CNY 101.84 million[22]. - Basic earnings per share rose to CNY 1.76, a 100% increase from the previous year[23]. - The net cash flow from operating activities surged by 280.01%, reaching approximately CNY 158.99 million[22]. - The company's oxygen business generated sales revenue of CNY 178.84 million, with healthcare oxygen molecular sieve sales accounting for approximately 37.28% of total revenue[87]. - The sales revenue of hydrogen molecular sieves reached CNY 22.77 million in the first half of 2021, representing a year-on-year growth of 86.38%[87]. Research and Development - The company is investing RMB 50 million in R&D for new technologies related to molecular sieves and gas separation[14]. - The company's R&D investment as a percentage of operating revenue increased to 5.39%, up from 3.74% in the previous year, marking a 1.65 percentage point increase[21]. - The company has achieved a significant increase in R&D investment, with total R&D expenses amounting to ¥16,735,105.90, a 146.07% increase compared to the previous period[68]. - The average salary of R&D personnel increased significantly to ¥150,758.66, compared to ¥45,808.97 in the previous period, indicating a focus on talent retention and motivation[77]. - The company holds a total of 20 authorized invention patents and 50 utility model patents as of the report date, with a total of 94 intellectual property rights[66]. Market Expansion and Strategy - Future outlook includes a projected revenue growth of 25% for the full year 2021, driven by market expansion and new product launches[14]. - Market expansion efforts include entering Southeast Asian markets, with an expected revenue contribution of RMB 30 million in 2022[14]. - The company is actively expanding its capacity in Southeast Asia to support its international development strategy, with projects expected to be completed by the end of 2021[89]. - The company aims to improve its market position and product structure to compete with international giants like Honeywell UOP and Arkema[63]. Product Development and Innovation - The company plans to launch two new products in Q3 2021, which are expected to contribute an additional RMB 100 million in revenue[14]. - The company is advancing projects in environmental governance and energy chemical fields, focusing on the development of catalysts and adsorbents for various applications[90]. - The company has developed core technologies for producing molecular sieves from raw powder to formed products, enhancing brand recognition and market share against competitors[42]. - The company is focusing on high-value-added products, particularly in the oxygen production sector, with successful applications in large-scale VPSA oxygen production projects[86]. Financial Position and Assets - The total assets of the company at the end of the reporting period were approximately CNY 1.33 billion, a 12.14% increase from the end of the previous year[22]. - The net assets attributable to shareholders increased by 6.75% to approximately CNY 1.04 billion[22]. - The company's total current assets amounted to ¥710,675,461.70, a slight decrease from ¥717,715,430.63 at the end of 2020, representing a decrease of approximately 1.5%[196]. - The cash and cash equivalents were reported at ¥258,980,163.03, an increase from ¥142,665,624.88 in December 2020, indicating a growth of approximately 81.5%[196]. - The total fixed assets reached ¥415,659,704.14, up from ¥351,455,661.48, marking an increase of approximately 18.3%[196]. Environmental and Social Responsibility - The company has implemented advanced environmental protection facilities, reducing production costs and pollutant emissions through recycling processes[83]. - The company has achieved a green coverage area of 31,358.9 m², representing a green coverage rate of 37.38% of the outdoor area[126]. - The company has actively participated in social welfare, providing 33,400 yuan in aid to the elderly and donating 4,000 yuan to impoverished families[128]. - The company invested 504,000 yuan in the repair of community roads to enhance local infrastructure[129]. Shareholder Commitments and Governance - The company reported a commitment from major shareholders, including the actual controller, to not transfer or delegate management of shares held prior to the IPO for 36 months[134]. - Shareholders are restricted from transferring more than 25% of their shares annually while serving as directors or senior management, and for six months post-departure[136]. - The company has established a commitment to not repurchase shares held prior to the IPO during the specified lock-up periods[138]. - Major shareholders, including the actual controller, have made commitments regarding share transfers and management during their tenure[139]. Risks and Challenges - The company faces risks related to product iteration, technology commercialization, and potential loss of core technical personnel, which could impact its competitive position[93]. - The domestic molecular sieve industry faces challenges in technology maturity and market application compared to developed countries, but opportunities for growth are increasing[33].